Clinical Trials Logo

Angiomyolipoma clinical trials

View clinical trials related to Angiomyolipoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05785052 Recruiting - Clinical trials for Renal Cell Carcinoma

Biomarkers of Renal Cancer

BRC
Start date: June 11, 2019
Phase:
Study type: Observational

The aim of the present study is the identification, in liquid biopsies, of a new molecular panel able to discriminate renal cancer patients from controls, to discriminate patients with a malignant lesion from those with a benign mass, to determine aggressiveness of RCC, and to differentiate the most common histological subtypes of RCC (clear cell, papillary 1, papillary 2, and chromophobe). This new molecular panel will be combined with clinical parameters to provide a screening test and to improve the accuracy and specificity of diagnosis, prognosis, and histological classification of renal cancer.

NCT ID: NCT05252585 Recruiting - Clinical trials for Renal Angiomyolipoma

A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)

Start date: May 1, 2023
Phase: Phase 4
Study type: Interventional

The purpose of this prospective study is to assess the safety and efficacy of everolimus in Taiwanese patients with renal angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC) . Only patients who fulfil the local reimbursement criteria of everolimus for TSC-AML will be included in this study.

NCT ID: NCT02887781 Recruiting - Clinical trials for Tuberous Sclerosis Complex

Clinical Presentation and Renal Outcome of Patients With Tuberous Sclerosis Complex and/or Renal Angiomyolipoma in the Great West Region of France

TSAR
Start date: August 13, 2015
Phase:
Study type: Observational

This study aims to investigate the factors (clinical, care-related and genetic) affecting renal outcome in patients with TSC (Tuberous sclerosis complex)